期刊文献+

尿毒症伴重度继发性甲状旁腺功能亢进症骨密度特征分析 被引量:3

The characteristics of bone mineral density in patients with uremia and severe secondary hyperparathyroidism
下载PDF
导出
摘要 目的研究尿毒症伴重度继发性甲状旁腺功能亢进症患者的骨密度改变特征,分析该组患者骨密度改变与临床特征之间的关系。方法回顾性总结2011年2月至2013年4月在本院接受甲状旁腺全切除联合自体前臂移植术的51例尿毒症伴重度继发性甲状旁腺功能亢进症患者的一般情况、临床特点、股骨近端和腰椎骨密度,及全切除手术所得甲状旁腺质量等数据。比较相同性别患者腰椎L1-L4之间、股骨近端不同部位之间骨密度的差异;对不同部位骨密度减少程度与上述观察变量之间的关系进行相关性分析。结果本组患者临床表现包括皮肤瘙痒、骨痛、身高缩短、面部变形和躯体变形等;血清iPTH高达2227.9±907.3 pg/ml;骨质疏松27例(52.9%),骨量减少23例(45.1%);男女性患者均显示L1至L4椎骨骨密度T值逐渐降低,男性骨密度T值L4显著低于L1(P=0.037),女性骨密度T值L4亦显著低于L1(P=0.039),男女性均显示股骨转子、股骨颈至Ward’s三角区的T值逐渐降低,男性Ward’s三角区T值显著低于股骨转子(P=0.025),女性Ward’s三角区和股骨颈T值显著低于股骨转子(P=0.009和P=0.023)。体重指数、血清白蛋白与骨密度值呈显著正相关,身高缩短、脊柱变形、胸廓变形、面部变形、血清碱性磷酸酶、血清iPTH、甲状旁腺质量与骨密度值呈显著负相关。结论骨质疏松和骨量减少广泛存在于尿毒症伴重度继发性甲状旁腺功能亢进症患者中;身体承重部位骨密度降低更严重;消瘦、低白蛋白血症、面部及躯干变形、iPTH严重升高、甲状旁腺增生程度重等因素提示骨质疏松风险增大。 Objective To investigate the characteristics of bone mineral density ( BMD ) in patients with uremia and severe secondary hyperparathyroidism ( SHPT) , and to analyze the possible relationship between the changes of BMD and clinical features. Methods Fifty one patients with uremia and severe SHPT , who underwent total parathyroidectomy with forearm autotransplantation , were enrolled in this study .The clinical data of all the patients , including the general condition , clinical feature , BMD of the proximal femur and the lumbar vertebrae , and the weight of parathyroids from surgery , were retrospectively analyzed .BMD of the lumbar vertebrae (L1-L4) and the proximal femur was compared in the patients with the same gender .The correlation analysis between the decrease of BMD and multiple variables was also performed .Results Pruritus, osteodynia, facial deformations, short statures, thoracocyllosis, spine malformations, and bowlegs were found in all or part of the patients with high serum iPTH level of 2227.9 ± 907.3pg/ml.Twenty-seven ( 52.9%) patients had osteoporosis, and 23 ( 45.1%) patients had osteopenia.BMD of L1-L4 declined gradually in men and women, while the T value of L4 was significantly lower than that of L1 ( P=0.037 in men and P=0.039 in women) .The T values of the femoral trochanter, the femoral neck, and the Ward’ s triangle also declined gradually.The T value of Ward’s triangle was significantly lower than that of the femoral trochanter (P=0.025) in men, while the T values of Ward’ s triangle and the femoral neck were significantly lower than that of the femoral trochanter ( P=0.009 and P=0.023 ) in women.BMI and serum albumin level were positively correlated with BMD. Shorten statures, thoracocyllosis, spine malformations, facial deformation, serum alkaline phosphatase level, serum iPTH level, and parathyroid weight were negatively correlated with BMD.Conclusion Osteoporosis and osteopenia are widely observed in patients with uremia and severe SHPT .The decrease of BMD in patients is more likely to appear in the bearing parts .Emaciation, low serum albumin levels, facial deformation, trunk malformation , high serum iPTH level , and large weight of parathyroid glands may indicate the increased risk of osteoporosis in patients with uremia and severe secondary hyperparathyroidism .
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2014年第5期524-529,共6页 Chinese Journal of Osteoporosis
关键词 骨密度 尿毒症 继发性甲状旁腺功能亢进症 Bone mineral density Uremia Secondary hyperparathyroidism
  • 相关文献

参考文献2

二级参考文献31

  • 1骨质疏松及骨矿盐疾病诊疗指南(讨论稿)[J].国际内分泌代谢杂志,2006,26(4):291-298. 被引量:47
  • 2张凌.慢性肾脏病甲状旁腺功能亢进症的病理生理及临床表现//张建荣,张凌.慢性肾脏病继发性甲旁亢[脚.北京:人民军医出版社,2010:82-114.
  • 3Moranne 0, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol, 2009, 20 : 164-171.
  • 4Goodman WG, Goldin J, Kuizon BD, et al. Coronary-arte~ calcification in young adults with end-stage renal disease who are undergoing dialysis. N Eng J Med,2000,342:1478-1483.
  • 5Teresa A, Joao MF. Cardiovascular risk in dialysis patients : X-ray vision on vascular calfications. Kidney Int, 2008,74:1505-1507.
  • 6Kidney Disease: Improving Global Outcomes (KDIGO) CKD- MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Snpp1,2009 ,'( 113 ) : S1-130.
  • 7Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol, 2008,3:836-843.
  • 8Cohen J, Diamond I. Leontiasis ossea, slipped epiphyses, and granulose cell tumor of testis with renal disease. Arch Pathol,1953, 56:488-500.
  • 9Dantas M, Costa RS, Jorgetti V, et al. Facial leontiasis ossea: a rare presentation of hyperparathyroidism secondary to chronic renal insufficiency. Nephron, 1991,58:475-478.
  • 10Lee VS, Martinez S. Leontiasis in secondary hyperparathyroidism. J Bone Miner Res, 1997,12 : 1952-1953.

共引文献31

同被引文献50

  • 1Raehner TD, Khosla S, Hoflauer LC. Osteoporosis: now and the future[J]. Lancet, 2011, 377(9773): 1276-1287.
  • 2Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients [J]. Kidney Int, 2014, 85(l): 166-173.
  • 3Kidney Disease: hnproving Global Outcmnes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD) [ J ]. Kidney Int Suppl, 2009, (113) : S1 -S130.
  • 4West SL, Lok CE, Langsetmo L, et al. Bone mineral density predicts fractures in chronic kidney disease[ J]. J Bone Miner Res, 2015, 30(5) : 913 -919.
  • 5Iinmri S,Mori Y,Akita W,et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5 D patients--a single-center cohort study [ J ]. Nephrol Dial Transplant, 2012, 27 ( 1 ) : 345 - 351.
  • 6Ketteler M, Elder GJ, Evenepoel P, et al. Revisiting KDIGO clini- cal practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference [ J ]. Kidney Int, 2015, 87 ( 3 ) : 502 -528.
  • 7Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/ DOQI clinical practice guidelines for management of dyslipidernias in patients with kidney disease [ J]. Am J Kidney Dis, 2003, 41 (4 Suppl 3) : S1 -$91.
  • 8Malluehe HH, Davenport DL, Cantor T, et al, Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis[J]. Clin J Am Soc Nephrol, 2014, 9(7): 1254 - 1262.
  • 9Baweto FC,Barreto DV, Moyses RM, et al. Osteoporosis in hemodi- alysis patients revisited by bone histomorphometry: a new insight into an old problem[J]. Kidney Int, 2006, 69(10) : 1852 - 1857.
  • 10Binici DN, Gunes N. Risk factors leading to reduced bone mineral density in hemodiaysis patients with metabolic syndrome [ J]. Ren Fail, 2010, 32(4): 469-474.

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部